key: cord-0729038-8s3fzpt0
authors: Kurai, Daisuke; Natori, Makiko; Yamada, Maho; Zheng, Richuan; Saito, Yuki; Takahashi, Hiroshi
title: Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in Japan
date: 2021-11-03
journal: Influenza Other Respir Viruses
DOI: 10.1111/irv.12928
sha: d3a753001776478470004b79381c5abdb3f28b11
doc_id: 729038
cord_uid: 8s3fzpt0

BACKGROUND: The frequency and clinical profile of respiratory syncytial virus (RSV)–acute respiratory disease (ARD) in older adults in Japan has not been well‐characterized. METHODS: This was a multicenter prospective observational cohort study to evaluate the occurrence rate of ARD in 1000 older adult participants (≥65 years) for 52 weeks during the 2019 to 2020 season. A multiplex polymerase chain reaction panel was used for pathogen detection in nasopharyngeal swab from participants diagnosed with ARD. Symptoms and impact of ARD was assessed using the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™). The study was registered at UMIN (https://www.umin.ac.jp/ctr/): UMIN000037891. RESULTS: RSV–ARD was detected in 24/1000 (2.4%) participants and RSV‐lower respiratory tract disease in 8/1000 (0.8%) participants. The median duration of RSV–ARD was 18 days. All 24 participants had utilized the medical services of outpatient visits and only 1 (4.2%) participant was hospitalized for RSV–ARD. The most common viruses other than RSV that caused ARD (detected in >10 participants) were human rhinovirus/enterovirus, parainfluenza 3, coronavirus OC43, human metapneumovirus, and influenza A/H1. The most frequent symptoms of RSV–ARD were cough, sore throat, nasal congestion, and expectoration. CONCLUSIONS: RSV was reported as a major pathogen for respiratory infections in older adults in Japan.

Respiratory syncytial virus (RSV) is a common pathogen responsible for mild cold-like symptoms to lower respiratory tract infection (LRTI).

Generally people recover within 2 weeks, but it can be serious in infants, children <5 years, older adults (especially ≥60 years), immunocompromised, or people with underlying cardio-pulmonary conditions. 1 Globally, in 2015, approximately 33.1 million children <5 years reported RSV-associated acute LRTI, of which 3.2 million were hospitalized and 59,600 died, while 336,000 older adults were hospitalized due to RSV-associated acute respiratory infection, of which 14,000 died. 2, 3 Annually, over 177,000 older adults are hospitalized and 14,000 die in the United States (US) with RSV infection. 1 Older adults have higher risk of severe complications from RSV due to immunosenescence. 1 A 4-year prospective study in the US during 1999 to 2003 showed that 3%-7% of healthy older adults, 4%-10% of high-risk patients, and 8%-13% of hospitalized patients had RSV infection. 4 Another prospective observational cohort study in Europe (EU) during 2018 to 2019 showed that RSV infection is prevalent in community-dwelling older adults (≥60 years) with an annual incidence of 2.1%-4.9%; however, it rarely causes severe disease. 5 In long-term care facilities, RSV is estimated to infect 5%-10% of residents per year with significant rates of pneumonia (10%-20%) and death (2%-5%). 6 In the EU and the US, RSV is increasingly recognized, including impact on older adults; however, little is known about RSV infection in Japan. 7 Several prophylactic vaccines against RSV disease in older adult populations are currently under development. As Japan has a significant population over 60 years of age (35.6 million), 8 it is important to understand the burden of RSV disease in this population.

The objectives of this study were to estimate the occurrence rate of RSV infection, and to characterize the RSV disease outcome in older adults in Japan.

Ambulatory adults (≥65 years) living in Japan in community or assisted-living or long-term care residential facilities, and who were, healthy or with clinically stable medical conditions, were enrolled.

Participants with acute respiratory disease (ARD) at consent and

Week 0 (baseline), or who had received experimental antiviral drugs or vaccines for RSV within 6 months prior to the study, or had a life expectancy <1 year, were excluded.

The study was conducted at 10 sites in Japan from April 2019 to July 2020. Participants were followed up bi-weekly (weekly during RSV season, predefined from 01 June 2019 to 30 November 2019) 9 through telephone to monitor ARD. Each participant was observed for 52 weeks from the day of registration or until withdrawal ( Figure 1 ).

The study was conducted in accordance with the principles defined in the Declaration of Helsinki, Ethical Guidelines for Medical and Health Research Involving Human Subjects, Japanese regulations, and sponsor policy. The occurrence rate of RSV infection in older adult population was conservatively estimated to be 2%. 4 A total of 1000 participants were expected to allow for precision of estimation of the true attack rate of 2%, as measured by the width of the two-sided 95% confidence interval (CI). The diagnosis and severity at ARD diagnosis by investigators, and the time from the onset day of ARD symptoms to the day of ARD diagnosis (ARD Visit Day 0) were also evaluated as post hoc analyses.

This was an exploratory descriptive study; therefore, no hypothesis testing was conducted. The precision of the estimate of the occurrence rate was determined using the Clopper-Pearson exact 95% F I G U R E 1 Schematic diagram of the study. Greyed cells in the above figure indicate scheduled activities to be performed at home. White cells in the above figure indicate scheduled activities to be performed at the study site. *Of which >30% aged 65 to 74 years and >30% aged ≥75 years and older (including >5% of 85 years and older as possible). **In the case that participants recovered and symptoms recurred, ARD was defined as a single episode or a separate episode of respiratory illness by the clinical judgment of the investigator; however, the episodes of respiratory illness that occurred >28 days of each other as a separate episode of illness were to be counted. 10 Abbreviations: ARD = acute respiratory disease, ICF = informed consent form, RiiQ™ = Respiratory Infection Intensity Questionnaire, RSV = respiratory syncytial virus CI. All participants having baseline (Week 0) data were included in the analyses. All data were summarized descriptively. 

RSV-ARD was detected in 24/1000 (2.4%) participants (95% CI: 1.54, 3.55) by RT-PCR; of which, 13/24 (54.2%) and 11/24 (45.8%) had Subtypes A and B RSV-ARD, respectively (Table 3 ).

RSV-LRTD, as assessed by the investigator was detected in 8/1000 (0.8%) participants (95% CI: 0.35, 1.57); 7 (0.7%) and 1 (0.1%) had Subtypes A and B RSV-LRTD, respectively ( Table 3) .

The median (range) duration of RSV-ARD was 18.0 (10 to 33) days (Table S1 ). The most frequent symptoms recorded by the participants (mean change of >1.0 in symptom score from baseline) for RSV-ARD were cough, sore throat, nasal congestion, and expectoration. For most participants (n = 15), symptoms improved by Day 14;

however, for few participants (n = 7), the symptoms lasted for 21 to 28 days after onset (data not shown). Respiratory tract symptoms tended to take longer to return to baseline for RSV and human metapneumovirus than for influenza A/H1 ( Figure S1 ). The body tempera- Severe morbidity and mortality were seen in older adults hospitalized with RSV infection in an earlier study conducted in the US. 21 Another study conducted in EU confirmed that RSV is prevalent in community-dwelling older adults. 5 Hence, there is a need for vaccine T A B L E 5 Summary of diagnosis of ARD by investigators (pathogens detected in >10 samples) This study has following limitations: the study was designed for only 1 RSV season in 2019 with 1000 participants, resulting that the relatively low numbers of cases reported in each pathogen make it difficult to compare disease characteristics among subgroups or pathogens; the impact of COVID-19 pandemic occurred in March 2020 was unknown on the occurrence of ARD by respiratory pathogens and the study site visits; there could be an underestimation of severe ARD cases requiring hospitalization given that 90% of participants were enrolled from general practitioner sites and a participant with severe symptoms could visit a hospital site other than study sites and such case was not recorded in the study.

RSV was reported as a major pathogen causing respiratory infection and represents a burden as significant as influenza in elderly Japanese community setting. The evidence of medical needs for development of vaccine to prevent RSV infection was generated.

Respiratory syncytial virus infection (RSV)

Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Respiratory syncytial virus infection in elderly and high-risk adults

Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study

Respiratory syncytial virus infection in adults

2018) Current status of RS virus vaccine development and global surveillance

Ministry of Internal Affairs and Communication

Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom

Development and validation of the intensity and impact of influenza questionnaire (Flu-iiQ). Value Health

Psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire Version 2 (RiiQ™) symptom scores for respiratory syncytial virus

The Barthel ADL Index: a reliability study

Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population

Is the Barthel Index an adequate assessment tool for identifying a risk group in elderly people living at home?

Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness

Lower respiratory tract infection in the community: associations between viral aetiology and illness course

Risk factors for severe respiratory syncytial virus infection in elderly persons

Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease

Winter viruses: influenza-and respiratory syncytial virus-related morbidity in chronic lung disease

Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults

Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in Japan

The authors appreciate the study participants, and also appreciate the investigators and study coordinators for their contributions to this study. The RiiQ™ was used under license provision by Measured Solutions for Health P/L, Australia. This work was supported by Janssen Pharmaceutical K.K.The writing support for manuscript was provided by SivaNagiReddy Tiyyagura, Vivek Rane, Kiran Chawla, Rajesh KS, and Pavithran Purushothaman from Kinapse (a Syneos Health ® Company).

The study was approved by the Saka General Hospital ethics committee (#18-03-49), and by the ethics committee at each study site.

Informed consent was obtained from all participants prior to enrolment.

No materials were reproduced from other sources.

The peer review history for this article is available at https://publons. com/publon/10.1111/irv.12928.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

https://orcid.org/0000-0001-9492-8798